Año 2023 / Volumen 115 / Número 6
Original
Adverse events of vonoprazan in the treatments of acid-related diseases: a systematic review and meta-analysis

294-300

DOI: 10.17235/reed.2022.9228/2022

Haiying Gong, Di Han, Sen Liu, Chengjiang Liu, Xiaolin Zhu, Diping Chen,

Resumen
Background and aims: vonoprazan, a novel potassium-competitive acid blocking agent, has better clinical outcomes in the treatment of acid-related diseases. However, some adverse events have been associated with vonoprazan for the treatment of acid-associated diseases. Therefore, this systematic review and meta-analysis aimed to explore the safety and tolerability of vonoprazan for acid-associated diseases. Methods: electronic databases were retrieved to determine randomized controlled trials (RCTs) of vonoprazan for acid-associated diseases with any adverse effects and discontinuation. Results: this systematic review and meta-analysis conforming to the selection criteria included 18 RCTs with a total of 7,932 participants. Compared with proton pump inhibitors, oral vonoprazan treatment showed no significant increase in the incidence of adverse effects (95 % CI = 0.987-1.095, p = 0.141). Diarrhea or loose stools analysis showed that there was a statistically significant difference between vonoprazan and proton pump inhibitors (PPIs) treatment (95 % CI = 0.661-0.966, p = 0.021). However, there was no significant difference in constipation, rash or eruption, nausea or vomiting, bloating or abdominal pain, dysgeusia, nasopharyngitis, neurological disorders, upper respiratory tract infection and abnormal investigations between vonoprazan and PPIs treatment. Conclusion: vonoprazan, which has better tolerability and safety, may significantly decrease diarrhea and loose stools in acid-related patients compared with PPIs. Our meta-analysis led to safer strategies for treating acid-related diseases. More high-quality studies with larger sample sizes are needed to further elucidate its efficacy and safety.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Artículos relacionados

Editorial

Uso seguro de los inhibidores de la bomba de protones

DOI: 10.17235/reed.2023.9834/2023

Instrucciones para citar
Gong H, Han D, Liu S, Liu C, Zhu X, Chen D, et all. Adverse events of vonoprazan in the treatments of acid-related diseases: a systematic review and meta-analysis. 9228/2022


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1323 veces.
Este artículo ha sido descargado 277 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 25/09/2022

Aceptado: 28/10/2022

Prepublicado: 10/11/2022

Publicado: 06/06/2023

Tiempo de revisión del artículo: 21 días

Tiempo de prepublicación: 46 días

Tiempo de edición del artículo: 254 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas